Boehringer Ingelheim Corporation Release: LUME-Lung 1: Nintedanib* Plus Chemotherapy Extends the Life of Lung Cancer Patients With Adenocarcinoma
6/3/2013 1:15:00 PM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
INGELHEIM, Germany--(BUSINESS WIRE)--The LUME-Lung 1 Phase III clinical trial results showed that the novel investigational compound nintedanib*, an oral triple angiokinase inhibitor, extended life by 2.3 months for non-small cell lung cancer (NSCLC) adenocarcinoma patients when added to docetaxel, versus placebo plus docetaxel.1 These results will be presented today at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Help employers find you! Check out all the jobs and post your resume.
comments powered by